<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">21742593</PMID>
      <DateCompleted>
        <Year>2012</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1769-6917</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>99</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Feb</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Bulletin du cancer</Title>
          <ISOAbbreviation>Bull Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[PI3K-AKT-mTOR pathway and cancer].</ArticleTitle>
        <Pagination>
          <StartPage>173</StartPage>
          <EndPage>180</EndPage>
          <MedlinePgn>173-80</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1684/bdc.2011.1384</ELocationID>
        <Abstract>
          <AbstractText>PI3K/AKT/mTOR pathway is an intracellular signalling pathway composed of different kinases. Many protein mutations are described in that pathway, and are responsible of dysregulation of cell growth, proliferation, survival and angiogenesis. Rapamycin is an antibiotic inhibiting mTOR. Different analogs of rapamycin are developed or being developed in antitumoral therapy, in which temsirolimus, everolimus and deforolimus, demonstrated antitumoral activity in renal cancer and mantle cell lymphoma, and many clinical trials are in progress in other tumors. In the future, predictive factors of response need to be identified; patient selection and associations with chemotherapy or with other targeted therapies should be explored.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Coutte</LastName>
            <ForeName>Laetitia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Hôpital Beaujon, service interhospitalier de cancérologie, 100, boulevard du Général-Leclerc, 92118 Clichy Cedex, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dreyer</LastName>
            <ForeName>Chantal</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sablin</LastName>
            <ForeName>Marie-Paule</ForeName>
            <Initials>MP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Faivre</LastName>
            <ForeName>Sandrine</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raymond</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
          </Author>
        </AuthorList>
        <Language>fre</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Rôle de la voie PI3K-AKT-mTOR dans le cancer et les thérapeutiques antitumorales.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Bull Cancer</MedlineTA>
        <NlmUniqueID>0072416</NlmUniqueID>
        <ISSNLinking>0007-4551</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>48Z35KB15K</RegistryNumber>
          <NameOfSubstance UI="C515074">ridaforolimus</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>624KN6GM2T</RegistryNumber>
          <NameOfSubstance UI="C401859">temsirolimus</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9HW64Q8G6G</RegistryNumber>
          <NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051058">Oncogene Protein v-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>W36ZG6FT64</RegistryNumber>
          <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002292" MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName>
          <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020522" MajorTopicYN="N">Lymphoma, Mantle-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051058" MajorTopicYN="N">Oncogene Protein v-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="Y">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2011</Year>
          <Month>7</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2011</Year>
          <Month>7</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">21742593</ArticleId>
        <ArticleId IdType="doi">10.1684/bdc.2011.1384</ArticleId>
        <ArticleId IdType="pii">S0007-4551(15)30495-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
